Flavocytochrome P450 BM3 is a member of the diflavin reductase enzyme family. Members include cytochrome P450 reductase, nitric oxide synthase, methionine synthase reductase and novel oxidoreductase 1. These enzymes show a strong preference for NADPH over NADH as reducing coenzyme. An aromatic residue stacks over the FAD isoalloxazine ring in each enzyme, and in some cases is important in controlling coenzyme specificity. In P450 BM3, the aromatic residue inferred from sequence alignments to stack over the FAD is W1046. + charge-transfer species, suggesting a relatively slow rate of release of NAD(P) + from reduced enzymes. Unlike wild-type enzymes, there is no formation of the blue semiquinone species observed during reductive titration of the W0146A/H FAD and reductase domains with dithionite or NAD(P)H. This is a consequence of elevation of the semiquinone/hydroquinone couple of the FAD with respect to the oxidised/semiquinone couple, and a concomitant ~ 100 mV elevation in the 2-electron redox couple for the enzymebound FAD (-320 mV, -220 mV and -224 mV in the wild-type, W1046A and W1046H FAD domains, respectively).
INTRODUCTION
Bacillus megaterium flavocytochrome P450 BM3 is a high activity fatty acid hydroxylase enzyme that has evolved from fusion of a eukaryotic-like NADPH-cytochrome P450 reductase (CPR) to a P450 in a single polypeptide (1) . The fusion provides an efficient electron transport system from NADPH, through the FAD and FMN cofactors in the CPR, and onto the heme b in the P450 (2) . P450 BM3 has the highest monooxygenase activity of any P450 system examined to date (3) . Molecular dissection has been used to generate the individual heme and CPR domains for structural, thermodynamic and kinetic studies (e.g. [4] [5] [6] [7] . The component flavodoxin-like (FMNcontaining) and ferredoxin reductase-like (FADcontaining) domains of the CPR have also been generated, supporting the hypothesis that the enzyme has a discrete domain organization, and that the BM3 CPR and other related enzymes evolved by fusion of genes encoding the smaller flavoproteins (8) . Molecular dissection of the related human CPR to produce component flavinbinding domains has been reported (9) . The isolated domains of human CPR exchange electrons and have thermodynamic properties almost identical to those of intact CPR (9, 10) . The availability of isolated domains has enabled detailed study of electron transfer mechanisms in wild-type and mutant proteins (11, 12) .
Flavocytochrome P450 BM3 belongs to the diflavin reductase family of enzymes, members of which contain both FAD and FMN cofactors in the same polypeptide chain. Other members of this class include eukaryotic CPRs (13) , mammalian methionine synthase reductase (MSR, 14) , human novel reductase 1 (NR1, 15) and the various isoforms of nitric oxide synthase (16) . Dihydroorotate dehydrogenase B (DHODB) also contains FAD and FMN cofactors bound noncovalently in discrete domains, and in addition binds an iron-sulfur cluster (17) . However, the modular construction of this enzyme, essential in nucleotide synthesis, is distinct from other members of the family. The eukaryotic NOS isoforms, like P450 BM3, contain heme b bound to an oxygenase domain covalently linked to the reductase domain (18) . In recent work, the reduction potentials for each of the couples of the flavin cofactors in P450 BM3, neuronal NOS, human CPR, human NR1 and MSR have been determined by anaerobic spectroelectrochemistry (6, 10, (17) (18) (19) .
Each member of the diflavin reductase family has a strong preference for NADPH over NADH as reducing coenzyme. This is of particular relevance for P450 BM3, which is recognized as an enzyme of biotechnological potential, owing to its efficiency as a regio-and stereo-selective oxygenase (20) . Through both rational engineering (by structure-guided site-directed mutagenesis) and forced evolution approaches, P450 BM3 variants have been generated with alkane, short chain alkanoic acid and polycyclic aromatic hydrocarbon oxygenase activities (e.g [21] [22] [23] . A potential obstacle to the exploitation of P450 BM3 is the high cost of the natural reducing coenzyme for the enzyme, and the relatively poor activity with less expensive NADH coenzyme. A number of reports have emerged concerning the rational engineering of coenzyme specificity, following the first successful study with the flavoprotein glutathione reductase (24) . Substantial switches in coenzyme specificity (~18,000-fold in the case of glutathione reductase) often require multiple mutations in the nicotinamide coenzyme-binding site. Recently, however, a single point mutation in both human CPR (25) (26) (27) , and (albeit to a lesser extent) in nitric oxide synthase (28) , was shown to be sufficient to effect a substantial switch in specificity towards that of NADH. In both cases, the residue targeted is aromatic and shields the reface of the FAD isoalloxazine ring; replacement with either histidine or a smaller non-aromatic amino acid facilitates excellent conversion of selectivity towards NADH in both cases.
In this paper, we report the isolation and detailed characterisation of two mutant forms (W1046H and W1046A) of the isolated FADdomain and diflavin reductase domains of flavocytochrome P450 BM3. From sequence alignment studies and modelling using the crystallographic structure of rat CPR, we infer that W1046 shields the FAD isoalloxazine ring analogous to the role of W677 and W676 in rat and human CPR, respectively (25) (26) (27) 29 , Figure  1) . We have performed a detailed study of the thermodynamic, spectral and kinetic properties of the W1046H and W1046A proteins. We show that mutation of W1046 effects a remarkable switch in coenzyme preference. Detailed stopped-flow kinetic and potentiometric studies of the W1046H and W1046A proteins are used to elucidate the thermodynamic and kinetic origins of this switch in specificity for the reducing coenzyme.
EXPERIMENTAL PROCEDURES

Molecular Biology
Oligonucleotide-directed mutagenesis of the P450 BM3 diflavin reductase domain was performed using the Stratagene Quik-Change kit, using plasmid clones for the P450 BM3 reductase domain (amino acid residues 473-1048 of the full length flavocytochrome) described previously as the templates for the reactions (7, 8) . Plasmid DNA was prepared by standard methods (30) . Oligonucleotide primers for mutagenesis were synthesized in the Protein and Nucleic Acid Chemistry Laboratory (PNACL) at the University of Leicester. The following primers were used for the mutagenesis reactions to create W1046A and W0146H variants of P450 BM3 flavin domains: 5'-CGCAAAAGACGTGCACGCTGGGTAAATT-3 ' (W1046H forward primer); 5'-AATTTACCCAGCGTGCACGTCTTTTGC-3' (W1046H reverse primer); 5'-CGCAAAAGACGTGGCGGCTGGGTAAATT-3 ' (W1046A forward primer); 5'-AATTTACCCAGCCGCCACGTCTTTTGCG-3' (W1046A reverse primer). Underlined regions indicate the section of the oligonucleotides modified from the wild-type sequence to produce the codon change required for the two amino acid substitutions. The reductase mutant plasmids were isolated and the entire CYP102A1 reductase DNA sequences determined to ensure that the desired mutation had been introduced, and that there were no secondary mutations.
Reductase mutant domains were amplified by PCR (amino acid residues 471-1048) using the following two oligonucleotide primers: 5'-GAACAGTCTGCTAAAACCATGGCAAAAAA GGCAGAAAACGCTC-3' (primer NcoI) and 5'-ACTAAACTACTTTTATCGGATCCTCTTTTTA AT-3'(primer BamHI). Underlined nucleotides indicate sites for the named restriction enzymes. PCR was performed using cloned Pfu DNA polymerase (Stratagene). Conditions were as follows: template DNA 50 ng, primers 150 ng, 100 µM dNTPs, 2.5 units Pfu polymerase in a 50 µl total reaction volume. PCR was performed using a Techne Genius thermocycler for 30 cycles of 95 °C (45 sec), 52 °C (1 min) and 72 °C (2.5 min) for denaturation, annealing and extension, respectively. Amplified cDNA was cloned into pET11d (Novagen).
These mutant reductase clones were used as templates to amplify the NADPH/FAD-binding domains (amino acid residues 664-1048) using the following two oligonucleotide primers: 5'-GCGCCGCGCATATGCCGCTTGCG-3' (primer NdeI) and 5'-ACTAAACTACTTTTATCGGATCCTCTTTTTA AT-3' (primer BamHI). Primer Nde I binds at the 5' end of the sub-gene encoding the FAD domain, and primer BamHI binds at the 3' end. The underlined nucleotides indicate the positions of engineered sites for the respective enzymes. The amplified cDNAs for the W1046H and W1046A FAD domains were cloned into plasmid expression vector pET11a (Novagen), by cutting the PCR products with restriction enzymes NdeI and BamHI at the engineered sites. The plasmid vector was digested with the same enzymes prior to ligation of vector and insert. Constructs were transformed into E. coli XL1 Blue and selected on LB agar/amplicillin plates. Similar reaction conditions for PCR and ligation were used as described for the reductase domains.
Expression and purification of mutant reductase and FAD domains
Production of the FAD (FAD-and NADPHbinding) and diflavin reductase (FAD-, FMN-and NADPH-binding) domains of wild-type flavocytochrome P450 BM3 has been described (6, 8) . The E. coli T7 RNA polymerase lysogen strain BL21 (DE3) was used to express the wildtype and FAD/reductase domain mutant (W1046A/H) proteins. Freshly transformed cells were cultured in Terrific Broth (TB) media (30) at 37 °C with vigorous agitation. At an OD 600 of 0.8, gene expression was induced by the addition of IPTG (1 mM) and culture was continued for a further 3 hours before harvesting cells. Recombinant bacterial cells expressing the FAD domains were broken by sonication and protein selectively precipitated by addition of ammonium sulfate to 60 % saturation (on ice). The ammonium sulfate protein pellet containing the FAD domain was harvested by centrifugation (15000 g, 30 mins, 4 ºC) and the pellet retained. A similar procedure was used for the reductase domains, with the exception that a 0-30 % ammonium sulfate fractionation was performed first, with the supernatant being retained and subjected to further fractionation (30-60 % saturation). At all stages following cell breakage, protein degradation was minimized by maintenance of samples on ice in a cold room, and by addition of protease inhibitors (Roche Complete protease inhibitor tablet). The final ammonium sulfate pellets were resuspended in, and dialysed against, 50 mM Tris.HCl (pH 7.0) containing 1 mM benzamidine hydrochloride, 1 mM DTT and 1 mM EDTA (Buffer A). Reductase and FAD domain samples were applied to a DEAE Sephacel column previously equilibrated with buffer A. Proteins were eluted using a linear gradient of KCl (0-500 mM) in the same buffer. Fractions containing the FAD domains were selected on the basis of colour and UV-visible absorption spectrum, pooled and dialysed overnight using 50 mM Tris.HCl (pH 7.2) containing 1 mM benzamidine hydrochloride (Buffer B) and applied to a Q-Sepharose column equilibrated with the same buffer. Protein was eluted using a linear gradient of KCl (0-500 mM) and fractions with an A 280 /A 450 ratio of < 10 were pooled and dialysed against 50 mM potassium phosphate (pH 7.0). For the reductase domains, the Q-Sepharose step was replaced by hydoxyapatite chromatography. Pooled reductase fractions from the DEAE Sephacel stage were dialysed against 50 mM potassium phosphate (pH 7.0, buffer C) and loaded onto the hydroxyapatite column. Protein was eluted using a linear gradient of buffer C to 250 mM potassium phosphate (pH 7.0) and fractions with an A 280 /A 450 ratio of < 8 (eluting at ~100 mM phosphate) were pooled and dialysed against 50 mM potassium phosphate (pH 7.0). Purity and integrity of the proteins was established by SDS-PAGE (15 % gels) and samples were stored at -70 °C in buffer C containing 50 % (v/v) glycerol following ultrafiltration (Centricon 30, Millipore) to ~ 0.5 -1 mM final concentration. SDS-PAGE (15%) indicated that the proteins were pure. The concentration of purified proteins was measured spectrophotometrically using molar extinction coefficients 11,300 M -1 .cm -1 for the FAD domains and 21,200 M -1 .cm -1 for the reductase domains, as described previously (7, 31, 32) .
Steady-state kinetic studies
All steady-state kinetic assays were performed using a Jasco V-550 UV/visible double beam spectrophotometer. The split-beam method was used to account for non-enzymatic ferricyanide and cytochrome c reduction by NAD(P)H coenzymes. Assays were set up typically containing 5-10 nM enzyme, potassium ferricyanide at 1.5 mM (for both FAD domains and reductase domains) and cytochrome c at 50 µM (for reductase domains). NAD(P)H was varied across a broad concentration range (~ 0-2 mM) to determine apparent K M values for the pyridine nucleotides. Reactions were performed in 50 mM potassium phosphate (pH 7.0) at 25 °C. In the assays, all components were added to the sample cuvette. The enzyme was not added to the reference cuvette and the volume was made up with the requisite volume of assay buffer. For the FAD and reductase domains, potassium ferricyanide reduction was monitored at 420 nm (∆ε 420nm (red-ox) = 1,020 M -1 cm -1 ). For the reductase domains, cytochrome c reduction was monitored at 550 nm ((∆ε 550nm (red-ox) = 22,640 M -1 cm -1 ) (33). To determine the apparent k cat values for NAD(P)H-driven reduction of the electron acceptors and the K M values for NAD(P)H, rate versus [NAD(P)H] data were fitted to a rectangular hyperbola.
Stopped-flow kinetic studies
Single turnover stopped-flow kinetic studies of flavin reduction in the W1046A/H FAD and reductase domains were performed using an Applied Photophysics SX.18 MVR stopped-flow spectrophotometer contained within a customized glove box (Belle Technology) to maintain anaerobic conditions (<5 ppm oxygen). Flavin reduction by NADH and NADPH was monitored at 450 nm. Rates of flavin reduction for mutant proteins were measured at 5 °C and 25 °C. Unless otherwise stated, all measurements were carried out in 50 mM potassium phosphate, pH 7.0 with 10 µM and 5 µM protein concentrations for FAD and reductase domains, respectively. All buffers by guest on November 19, 2017 http://www.jbc.org/ Downloaded from 6 were made oxygen-free by evacuation and extensive bubbling with oxygen-free argon before use. Prior to stopped-flow studies, protein samples were fully oxidized by treatment with potassium ferricyanide; excess ferricyanide was removed by rapid gel filtration in the glove box (Pharmacia PD-10 column).
Flavin reduction on mixing of reductase and FAD domains with NADPH and NADH was monitored at 450 nm. Absorption transients from the stoppedflow experiments were fitted to appropriate exponential functions using Spectrakinetics software (Applied Photophysics). Observed rate constants for flavin reduction by NADH showed a hyperbolic dependence on coenzyme concentration, and data were fitted to Equation 1 (31) to determine the apparent enzyme-coenzyme dissociation constant, K, and the limiting rate of hydride transfer (k lim ).
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For studies of flavin re-oxidation in single and multiple-wavelength stopped-flow modes, FAD and reductase enzymes were reduced to the 2 and 4-electron level with sodium dithionite in the presence of mediators (6 µM phenazine methosulfate, 15 µM 2-hydroxy-1, 4-naphthoquinone, 1.5 µM methyl viologen, and 3 µM benzyl viologen). Excess sodium dithionite and mediators were removed by gel filtration and their absence ensured by spectrophotometric readings of a fully reduced sample of each preparation. These proteins were then mixed rapidly with buffered NADP + or NAD + (50-1000 µM). Pseudo-first-order conditions were always maintained by keeping coenzyme concentration at least 10-fold greater than enzyme concentration in all stopped-flow analyses.
Stopped-flow, multiple-wavelength absorption studies were carried out using a photodiode array detector and X-SCAN software supplied with the Applied Photophysics instrument. Reactions were typically performed up to 1 second (although some spectra were recorded over longer timescales) after the initial mixing event, and the first spectrum was recorded 1.3 milliseconds after mixing. NADH and NADPH (typically in the concentration range 50 µM-10 mM) were mixed with oxidized enzymes (typically 5-10 µM). NAD + and NADP + (typically 50 µM to 1 mM) were mixed with fully reduced enzymes (typically 5-10 µM).
Potentiometry
Potentiometric redox titrations to determine the midpoint reduction potentials of the FAD and FMN cofactors in the W1046A/H domains were performed in a Belle Technology glove-box under a nitrogen atmosphere, as described previously (10) . All solutions were degassed under vacuum with argon. Oxygen levels were always maintained at less than 2 ppm. 100 mM potassium phosphate, pH 7.0, containing 10 % v/v glycerol (titration buffer) was used in all potentiometric titrations, and the protein was applied to a Pharmacia PD-10 desalting column in the anaerobic box, pre-equilibrated with degassed titration buffer, to ensure removal of all traces of oxygen. The protein solutions (typically 25 -50 µM in ~5 ml titration buffer) were titrated electrochemically according to the method of Dutton (34) using sodium dithionite as reductant and potassium ferricyanide as oxidant. Dithionite and ferricyanide were delivered in approximately 1-2 µl aliquots from concentrated stock solutions (typically 10-50 mM). Mediators (2 µM phenazine methosulfate, 5 µM 2-hydroxy-1, 4-naphthoquinone, 0.5 µM methyl viologen, and 1 µM benzyl viologen) were added to facilitate electrical communication between enzyme and electrode, prior to titration. The mediators are effective in the range between +100 to -480 mV, as described previously (6, 10) . The electrode was allowed to stabilize between each addition of reductant/oxidant. Spectra (300-800 nm) were recorded using a Cary UV-50 Bio UV-Visible scanning spectrophotometer, using a fibre optic probe inside the glove box connected to the external spectrophotometer. The electrochemical potential of the solution was measured using a Hanna pH 211 meter coupled to a Pt/Calomel electrode (ThermoRussell Ltd.) at 25 ± 2 °C. The electrode was calibrated using the Fe 3+ /Fe 2+ EDTA couple as a standard (+108 mV). A factor of +244 mV was used to correct relative to the standard hydrogen electrode. Data manipulation and analysis were performed using Origin software (Microcal). For titration of the FAD mutants, absorbance data at 462 nm (W1046H FAD/reductase), and 475 nm and 469 nm (W1046A FAD and reductase) were plotted against applied potential to determine the FAD oxidized/hydroquinone couples. Data for the FAD domains were fitted to both the Nernst equation and to Equation 2, which represents a 2-electron redox process derived by extension to the Nernst equation and the Beer-Lambert law, as described previously (10, 34 
In this equation, A is the total absorbance; a, b and c are the component absorbance values contributed by a flavin in the oxidized, semiquinone and reduced states, respectively. E is the observed potential; E' 1 is the midpoint potential for the oxidized/semiquinone couple and E' 2 is the midpoint potential for the semiquinone/reduced couple.
For the redox titrations of the W1046A and W1046H reductase domains, data were fitted to Equation 3, describing a 4-electron redox process, as described in previous studies (6, 10) . To enable the fitting process, data for the redox couples of the FMN from previous studies were fixed in the initial fitting regime (31 
Equation 3
In Equation 3 , A is the total absorbance; a, b and c are component absorbance values contributed by one flavin in the oxidized, semiquinone and reduced states, respectively; and d, e and f are the relevant absorbance values for the second flavin. E is the observed potential; E' 1 and E' 2 are the midpoint potentials for oxidized/semiquinone and semiquinone/reduced couples, respectively, for the first flavin, and E' 3 and E' 4 are the corresponding midpoint potentials for the second flavin.
Materials
Dpn I restriction enzyme and Pfu DNA polymerase were purchased from Stratagene (UK). Restriction enzymes and DNA ligase were purchased from New England Biolabs (NEB), UK. All other reagents were purchased from Sigma (Poole, UK) and were of the highest grade available.
RESULTS
Expression and purification of wild-type and W1046 mutants of P450 BM3 diflavin reductase and FAD domains
Constructs encoding the W1046A and W1046H diflavin reductases and FAD domains (hereafter referred to as pRedW1046A/H and pFADW1046A/H, respectively) and wild-type domains were transformed into E. coli strain BL21 (DE3) and expressed/purified as described in the Experimental Procedures section. Previous studies on wild-type domains have shown that the affinity resin 2', 5'-ADP agarose can be used to purify the NADPH-binding proteins (e.g. 7, 31, 32). However, the mutant FAD and diflavin reductase proteins bound only weakly to this resin. This suggests that the mutations have disrupted the coenzyme-binding site, which might reflect altered affinity for the coenzyme in kinetic studies. For this reason, purification of the enzymes was achieved using ion exchange chromatography procedures, as described in the Experimental Procedures section. Despite this difference in behaviour during column chromatography, the expression level of the mutant proteins was comparable to the wild-type proteins, and all proteins were ultimately purified in similar yield.
Absorption features of FAD and diflavin reductase proteins
The absorption spectra of wild-type and the W1046H and W1046A FAD domains indicate an altered environment for the flavin isoalloxazine ring ( Figure 2A) . Similarly, the absorption spectra of the W1046H and W1046A diflavin reductase proteins were perturbed compared to wild-type by guest on November 19, 2017 http://www.jbc.org/ Downloaded from 8 protein ( Figure 2B ). The absorption maxima for the two flavin peaks in the W1046A and W1046H FAD domains are red-shifted ( Figure 2A ). Maxima are located at 454 nm and 381 nm for the wild-type FAD domain, at 462 nm and 388 nm and at 475 nm and 396 nm for the W1046H mutant and W1046A mutants, respectively. The absorption at ~390 nm is more intense relative to the ~460 nm for the W1046A FAD domain, and the shoulder on the 460 nm peak is slightly less pronounced. This indicates that the flavin isoalloxazine ring is in a less hydrophobic environment, perhaps reflecting exposure of the FAD to solvent. Similar effects have been observed in recent studies of F1395A/S mutants of rat neuronal nitric oxide synthase (NOS) FAD domain (28, 35) in which the corresponding FADshielding residue was targeted by mutagenesis.
The spectral contribution of the FMN cofactor (which is unlikely to be perturbed significantly by the mutation of the putative FAD-shielding residue) overlays that of the FAD cofactor in the wild-type and mutant diflavin reductases. Consequently, the contribution made by the FMN cofactor partially obscures the effects of mutation on the absorption properties of the FAD ( Figure  2B ). That said, absorption shifts of a similar nature to those present in the isolated W1046H and W1046A FAD domains are observed in the corresponding W1046H and W1046A diflavin reductase proteins. The absorption maxima for the wild-type protein are located at 456 and 385 nm. For W1046H and W1046A diflavin reductases, absorption maxima are located at 462 nm and 388 nm (W1046H) and at 469 nm and 390 nm (W1046A). The shorter wavelength flavin band is also slightly increased in intensity relative to the longer wavelength band (by comparison with wild-type and W0146H enzymes) for the W1046A diflavin reductase, consistent with a less hydrophobic environment for the enzyme-bound FAD.
The absorption spectra of W1046A, W1046H and wild-type FAD domains reduced with excess NAD(P)H (100 µM) or with dithionite under aerobic conditions are shown in Figure 3 . The addition of dithionite resulted in the near-complete bleaching of absorption across the visible absorption range for the wild-type FAD domain ( Figure 3A) , with some residual neutral blue semiquinone species. This is consistent with previous work and the negative potential of the wild-type FAD semiquinone/hydroquinone couple. Reduction of wild-type FAD domain by either NADH or NADPH produced spectral signatures indicative of mainly blue semiquinone FAD, consistent with our previous work (6, 7, 31) . The semiquinone species is recognised by the distinct absorption feature with maximum at ~585 nm, as previously observed for the NADPH-reduced FAD domain (7, 8) . For the W1046H mutant ( Figure  3B ), the reduction of the FAD cofactor to the hydroquinone form is virtually complete with dithionite, and the blue semiquinone feature is not obvious on addition of either NADH or NADPH. There is, however, development of a broad absorption feature in the long wavelength region, with absorption increasing in intensity steadily from ~ 520 nm and extending out beyond 700 nm. This spectrum is consistent with the development of a charge-transfer (CT) species in which the oxidised pyridine nucleotide (NAD [P] + ) remains bound to the hydroquinone form of the flavoprotein. The spectrum is flat in this region for the dithionite-reduced W1046H FAD domain. The spectra obtained for reduction of the W1046A FAD domain shows some similarities to those for the W1046H FAD domain, except that the CT band is much more intense for the NADH-and NADPH-reduced forms ( Figure 3C ). There also appears to be a small qualitative difference between the CT spectra for the NADH-and NADPH-reduced enzymes. A similar CT species is also observed for W1046A FAD domain when dithionite is used as reductant. In the case of the W1046A enzymes, this likely reflects the very tight binding of NAD(P) + to the mutants on purification from E. coli. A similar observation was made for the Y308S mutant of spinach ferredoxin reductase (36) . Extensive dialysis results in displacement of the tightly bound NAD(P) + from the W1046A enzymes, resulting in the loss of the CT spectrum on dithionite reduction, as can be seen from the redox titration data for the W1046A FAD domain (see Figure  7B ). Thus, mutagenesis of W1046 does not prevent flavin reduction, but the optical spectra suggest that (i) release of oxidised coenzyme from the mutant proteins is impaired, leading to the development of charge-transfer character for the reduced enzyme-NAD(P) + complex, and (ii) the thermodynamic properties of the FAD are significantly altered, since NADH and NADPH effect a more complete conversion to the hydroquinone form, with negligible blue semiquinone apparent.
Steady-state kinetic properties of wild-type and W1046A/H FAD domains and diflavin reductases
Kinetic parameters for reduction of potassium ferricyanide by the wild-type, W1046A and W1046H FAD domains were established in steady-state assays using both NADPH and NADH as reducing coenzyme. Similar assays were performed for the wild-type and mutant diflavin reductase proteins. The kinetics of NADH-and NADPH-dependent reduction of cytochrome c (which occurs specifically via the FMN domain of the enzymes) was also characterized for the diflavin reductase enzymes. These cytochrome c reduction assays allow one to examine effects on inter-flavin (FAD-to-FMN) electron transfer as a result of mutating W1046.
Kinetic parameters obtained for the reduction of ferricyanide by the isolated FAD domains are presented in Table 1 . The apparent K M values for NADPH in the wild-type and W1046A FAD domains are similar, but the K M value for NADPH in the W1046H FAD domain is elevated (4.2-fold) compared to wild-type. The apparent k cat value for the W1046H FAD domain with NADPH is increased 2.4-fold with respect to wild-type, while that for the W1046A FAD domain is decreased 4.3-fold. The net effect on catalytic efficiency (k cat /K M ) for NADPH-dependent ferricyanide reduction by the FAD domains is that the W1046H and W1046A FAD domains are 1.7-fold and 5.9-fold less efficient than wild-type, respectively (Table 1) . Kinetic parameters obtained for the diflavin reductase enzymes with NADPH as reducing coenzyme are also shown in Table 1 . In this case, the K M values for NADPH are decreased 4.7-fold (W1046H) and 3.8-fold (W1046A) compared to wild-type. The turnover values (k cat ) follow a similar trend to that seen for the FAD domains, with the turnover number for the W1046H reductase being 1.4-fold higher than wild-type, and that for the W1046A reductase being 5.8-fold lower. The net effect on catalytic efficiency (k cat /K M ) for NADPH-dependent ferricyanide reduction by the reductase enzymes is a reduction in efficiency of 1.5-fold for W1046A and an increase of 6.7-fold for W1046H (Table 1) .
A switch in coenzyme preference has been observed in human CPR and rat neuronal nitric oxide synthase (and its isolated FAD domain) following mutagenesis of FAD-shielding residues (27) (28) (29) 35) . A goal of the work described herein was to engineer a switch in coenzyme preference by targeting the putative FAD-shielding residue (W1046) in the FAD domain and reductase portion of flavocytochrome P450 BM3. Turnover assays with NADH revealed that the W1046A and W1046H FAD domains and reductase enzymes had improved kinetic properties with NADH as reducing coenzyme ( 22 -fold (W1046A) higher than wild-type, producing an overall improvement in catalytic efficiency (from k cat /K M quotients for NADH, subsequently referred to as specificity constants) of ~857-fold (W1046H) and 3786-fold (W1046A). Thus, for the W1046H FAD domain and W1046H reductase enzymes there is a ~100-fold and 128-fold switch, respectively, in specificity from NADPH towards NADH (from the ratios of specificity constants for NADPH-and NADH-dependent ferricyanide reduction; see final column in Table 1 ). For the W1046A FAD domain and W1046A reductase, the switch in specificity is 3284-fold and 5752-fold, respectively. Clearly, the nature of the FAD-shielding residue in flavocytochrome P450 BM3 is critical to coenzyme selectivity. As ferricyanide reduction occurs predominantly from the FAD cofactor, it was also of interest to investigate the effects of the mutations on cytochrome c reduction, which occurs almost exclusively from the FMN domain.
Any effects of the mutation on inter-flavin electron transfer would be revealed in this type of assay.
Kinetic parameters derived from studies of NADPH-driven reduction of cytochrome c (Table  2) indicate that the apparent Michaelis constant for the coenzyme is reduced 2.9-fold and 13-fold for the W1046H and W1046A diflavin reductases, respectively. The turnover number for W1046H reductase is, within error, identical to that of wildtype reductase, but that for W1046A reductase is diminished 10-fold. The net effects on catalytic efficiency with NADPH are a 2.75-fold increase with W1046H and a 1.3-fold increase with W1046A. The kinetic parameters for the NADHdependent reduction of cytochrome c mirror the changes observed following mutation in the ferricyanide reduction assays. The k cat values are increased over wild-type reductase by 9.8-fold and ~8.4-fold for W1046H and W1046A reductases, respectively. The K M values are 69-fold (W1046H) and 253-fold (W1046A) lower than for wild-type. The net effect on catalytic efficiency with NADH is a ~700-fold increase for W1046H reductase and a 2192-fold increased for W1046A reductase (Table 2) .
To evaluate fully the switch in pyridine nucleotide specificity from NADPH towards NADH in wildtype and W1046A/H mutant reductases, the ratios of the specificity constants for NADH-and NADPH-dependent cytochrome c reduction were compared for wild-type and each mutant ( Table 2) . For the wild-type reductase, NADPH is used more efficiently than NADH for cytochrome c reduction by a factor of 12000-fold. This decreases to 47-fold for the W1046H reductase, and further to only 7.0-fold for W1046A reductase. These parameters indicate a 255-fold switch (W1046H reductase) and a 1709-fold switch (W0146A reductase) in coenzyme specificity from NADPH towards NADH.
Stopped-flow studies of flavin reduction in wild-type and mutant FAD domains and diflavin reductases
We analysed the kinetics of flavin reduction in the W1046A and W1046H enzymes using stoppedflow methods to investigate the formation and decay of any intermediates and to define limiting rate constants for flavin reduction. In photodiode array studies, spectra were collected during reduction of the enzymes by both NADPH and NADH. For the W1046H FAD domain (15 µM) mixed with NADPH (50 µM) or NADH (50 µM; Figure 4A ), a relatively smooth transition was observed from the oxidised to the hydroquinone forms. There is some development of long wavelength absorption as the reaction progresses, consistent with the proposed formation of a FADH 2 -NADP + CT species, as seen in the static titration. Following FAD reduction in the wildtype FAD domain, a similar phenomenon is observed with some long wavelength CT formation, as previously reported (31) . On longer timescales, electronic disproportionation occurs which generates the blue semiquinone form of the flavin in the wild-type FAD domain (7, 31) . This does not occur with the W1046H FAD domain, and the end point of the reaction appears to be formation of a reduced enzyme-oxidised nicotinamide coenzyme charge-transfer complex. With the W1046A FAD domain, again conversion from oxidised flavin to the hydroquinone is seen as the enzyme is reduced by either NADPH or NADH ( Figure 4B ), but in these cases a more intense charge-transfer absorption is observed at long wavelength. Again, disproportionation of this species to form a blue semiquinone is not observed. The intensity of the charge-transfer species in NADH-and NADPH-reduced W1046A FAD domains is substantially larger than observed for either wild-type or W1046H FAD domains (31) . There appears to be a single isosbestic point in the spectral conversion between oxidised flavin and the FADH 2 -NADP + charge-transfer species, and this is most clearly observed at ~532 nm for the NADH-and NADPH-reduced W1046A FAD domains (e.g. Figure 4B ).
Reduction of the diflavin reductase W1046 mutant enzymes was also studied by stopped-flow photodiode array spectroscopy (see Figures 4C  and 4D ). With NADH and NADPH, reduction of the W1046H enzyme occurs without development of charge-transfer character in the long wavelength region (e.g. Figure 4C ). Unlike with wild-type reductase, electronic disproportionation to form a blue semiquinone species does not occur following enzyme reduction. Likewise, with the W1046A reductases a blue semiquinone signal does not accumulate following reduction of the flavin with NADPH or NADH, but a strong FADH 2 -NAD(P) + charge-transfer band does develop as the flavin is reduced (e.g. Figure 4D ). The charge-transfer band is less intense than that developed with the isolated W1046A FAD domain (compare Figures 4B and  4D) . A similar charge-transfer species was detected in reactions of wild-type FAD domain, but not wild-type reductase, with nicotinamide coenzymes (31) .
In parallel studies, we investigated the reaction of 2-electron reduced W1046A/H FAD domains and 4-electron reduced W1046A/H reductase domains with NAD(P) + . In all cases, there was rapid development of a charge-transfer complex (similar to that seen at the end point of the respective forward reactions between NAD(P)H and the oxidized domains) with no significant reduction of the pyridine nucleotide. These results are consistent with the results of potentiometric studies reported below.
To analyse further the kinetics of flavin reduction and CT complex formation, we undertook single wavelength stopped-flow studies at 450 nm. Typical data for these transient kinetic reduction studies on the W1046A and W1046H FAD domains and reductase enzymes with NAD(P)H are shown in Figure 5 . Kinetic parameters from the 450 nm data are collected in Table 3 . With wild-type FAD domain and the reductase enzyme, the observed rate constant for flavin reduction (from analysis of the 450 nm transients) shows a hyperbolic dependence on coenzyme concentration (31) . With the W1046A and W1046H FAD domains and reductase enzymes, however, the observed rate of flavin reduction with NADPH as reductant was found to be constant across the coenzyme concentration range studied (0.05 to 1 mM), suggesting that the W1046 mutant enzymes bind the coenzyme with higher affinity compared with the corresponding wildtype proteins. The observed rates of flavin reduction, however, are slower in the mutant proteins (Table 3 (31) . Absorption transients at 450 nm collected for the W1046A FAD domain were more complex (e.g. Figure 5A ). In this case, transients were best fitted using a triple exponential function [137 s -1 (amplitude ~20 % of total observed absorption change), 9.2 s -1 (amplitude ~30 %) and 3.2 s -1 (amplitude ~50 %) at 5 °C and 100 µM NADPH]. The amplitudes remained relatively constant across the coenzyme concentration range (50 to 500 µM) and observed rates were independent of coenzyme concentration. The origin of the three phases is uncertain, but each contributes significantly to the absorption change at 450 nm, and thus reports on flavin reduction.
For W1046H reductase, transients were biphasic and observed rates were independent of NADPH coenzyme concentration across the range used in the analyses (0.05 to 1 mM); observed rates for the two phases were 93.8 s -1 (amplitude ~85 % of total observed absorption change) and 5.3 s -1 (amplitude ~15 %) (5 °C and 50 µM NADPH). Again, absorption transients for the W1046A reductase were more complex. Absorption transients were best described by a triple exponential function and observed rates of 204 s -1 (amplitude ~25 % of total absorption change), 6.4 s -1 (amplitude ~30 %) and 1.4 s -1 (amplitude ~45 %) were obtained at 5 °C and 50 µM NADPH. As with the W1046A FAD domain, the contribution made by each phase to the total absorption change was apparently independent of coenzyme concentration.
A dependence of flavin reduction rate on coenzyme concentration was observed when using NADH as reducing coenzyme. In this case, absorption transients obtained for wild-type, W1046H and W1046A FAD domains were apparently monophasic. However, in the case of the W1046A FAD domain, control experiments using the stopped-flow instrument (mixing enzyme with coenzyme-free buffer) indicated that a very fast phase of absorption change occurs on mixing the protein with NADH. This phase is largely lost in the dead-time of the instrument, and therefore likely has a rate constant of >800 s -1 , and may contribute ~30-50 % to the overall flavin absorption change. Absorption transients for wildtype reductase enzyme were biphasic; the slower phase contributed ~20 % of the total absorption change and the rate of this phase was independent of coenzyme concentration, consistent with previously published data for the wild-type reductase (31) . In the case of W1046A and W1046H reductases, absorption transients were also biphasic. However, for W1046A reductase, as with the W1046A FAD domain, a significant proportion of the overall absorption change (30 % or more) is lost in the mixing time of the instrument ( Figure 5B ). From the data for the W1046H variants, the limiting values for NADHdependent flavin reduction (k lim ) were found to be 28-fold and 19-fold higher, respectively, for W1046H reductase and W1046H FAD domains compared to wild-type enzymes (Table 3) . Marked improvements in apparent dissociation constants (K values) for NADH are also seen for the W1046H enzymes (9.6-fold and 17-fold for FAD domain and diflavin reductase, respectively). Based on fitting of the accessible rate data versus NADH concentration, even greater improvements in NADH binding are observed for the W1046A enzymes over wild-type (545-fold and 225-fold lower for the FAD domain and diflavin reductase domain, respectively) ( Table 3) .
Potentiometric measurements
To examine further the basis for altered electron transfer properties observed in both steady-state and stopped-flow kinetic assays, the reduction potentials of the flavins in both the FAD domains and reductase enzymes were determined by anaerobic spectroelectrochemistry, as described previously (31) . Previous studies with intact P450 BM3, the reductase and FMN domains revealed an intriguing difference regarding the redox properties of the P450 BM3 FMN cofactor compared with the properties of the corresponding FMN cofactor in related diflavin reductases (e.g. human cytochrome P450 reductase) and structurally-related prokaryotic flavodoxins (37, 38) . In P450 BM3, the FMN semiquinone is not stabilized to the same extent as in the other proteins (e.g 10) which accounts for the lack of observation of significant amounts of blue semiquinone during redox titrations. The wild-type P450 BM3 FAD domain, however, does stabilise a neutral blue semiquinone during redox titration. The reduction potentials of the oxidized/semiquinone (E 1 ) and semiquinone/hydroquinone (E 2 ) couples of the BM3 FAD domain have been determined as -264 ± 3 mV and -375 ± 4 mV, respectively (31) . Potentiometric titrations of the W1046A and W1046H FAD domains indicated that a blue semiquinone is no longer stabilized on the FAD cofactor in these proteins during equilibrium redox titration ( Figure 6 ). Midpoint potentials of -220 ± 3 mV (W1046A) and -224 ± 3 mV (W1046H) for the two electron redox couple (E 12 ) of the FAD cofactor were calculated. These E 12 values are ~100 mV more positive than those for the corresponding couple in the wild-type FAD domain (31) .
The lack of stabilization of the blue semiquinone in the FAD domain of the W1046A and W1046H reductase enzymes complicates spectral analysis of the absorption versus potential data for these proteins. Since there are no semiquinone signals that are assignable to either of the flavin cofactors, absorption data near the oxidized flavin maxima for the W1046A and W1046H reductases (475 nm and 462 nm, respectively) were also fitted to Equation 3 as described in the Experimental Procedures section. This produced estimates of the E 12 values of the W1046A/H FAD domains as -206 ± 5mV/-204 ± 6 mV. These values are consistent with those determined for the mutant FAD domains, and indicate that (as with the wildtype reductase) the FMN domain has relatively little thermodymamic effect on the behaviour of its linked FAD domain (6, 31) .
Discussion
The role of aromatic stacking residues close to the FAD cofactor in diflavin reductase enzymes, and in the structurally related ferredoxin/flavodoxin reductases, has been studied in cytochrome P450 reductase, nitric oxide synthase and pea ferredoxin reductase (e.g. [25] [26] [27] [28] 36) . In this paper, we have carried out detailed studies of the role of W1046 that, from sequence alignments with other diflavin reductase proteins, is inferred to stack over the FAD cofactor in BM3 reductase. The role of this residue in the mechanism of electron transfer is of interest as similar studies with human cytochrome P450 reductase indicate that the corresponding residue (W676) is highly mobile. This is an essential property of the side chain that allows reduction of the FAD cofactor by reducing coenzyme (39) . The ability to switch coenzyme specificity in human cytochrome P450 reductase by mutagenesis of W676 (40), and to a lesser extent in nitric oxide synthase by mutagenesis of F1395 (35, 41) , has important biotechnological implications for similar studies with P450 BM3. This arises owing to the capacity of wild-type and mutant forms of P450 BM3 to catalyse regio-and stereo-specific oxygenation of compounds of industrial and biotechnological importance, including alkanes, substituted styrenes and arachidonic acid (e.g. [21] [22] [23] 42) .
Studies with human CPR indicate that the mobility of Trp-676 is required to facilitate the binding of the NMN region of NADPH over the enzymebound FAD (27, 40) . When this residue is replaced by alanine the binding of NADH is improved, as is the overall catalytic performance with this coenzyme. The principal effect is on coenzyme binding (40) , whereas similar studies with nitric oxide synthase indicate that the major component of the switch in coenzyme specificity is an improvement in the steady-state turnover value (35) . Previous mutagenic studies on mammalian CPR have shown that disruption of residue R597 in the 2' phosphate-binding site (a site largely conserved in P450 BM3) substantially diminishes NADP(H) binding, but has relatively little effect on NAD(H) binding (43) . By contrast, our studies with the W1046A and W1046H FAD domains and reductase enzymes of P450 BM3 demonstrate that an effective switch in pyridine nucleotide specificity can be engineered by targeting the putative FAD shielding residue. The switch in coenzyme specificity is substantial: 5714-fold and 126-fold, respectively, for the W1046A and W1046H reductase enzymes in steady-state turnover with ferricyanide as electron acceptor. The switch in coenzyme specificity observed with the W1046A BM3 reductase is large compared with reported studies on nitric oxide synthase (48.5-fold for the F1395S mutant of neuronal NOS in cytochrome c reduction) and human CPR (1090-fold for the W676A mutant in cytochrome c reduction) (25, 28) . These findings are promising in terms of generating NADHspecific variants of P450 BM3 for biotechnological exploitation. That W1046 also plays a role in displacing oxidised nucleotide from the reduced FAD domain of BM3 reductase is apparent from the strong charge-transfer bands developed in the mutant reductase proteins. In wild-type BM3 reductase, these charge-transfer species are not stabilised to any significant extent in stopped-flow studies, but unlike the mutant proteins the wild-type enzyme disproportionates to form the blue semiquinone species following reduction by coenzyme. This latter observation suggests that the blue semiquinone species is not stabilised in the W1046H and W1046A reductases: a suggestion that has been confirmed by potentiometric analysis of the wild-type and W1046H and W1046A proteins. The relative destabilisation of the blue semiquinone species in the W1046H and W1046A enzymes likely contributes to the observed stabilisation of the FADH 2 -NADP + charge-transfer species.
Most previous studies reporting the effects of mutating the FAD-shielding residue in enzymes related to P450 BM3 have not analysed thermodynamic consequences on the reduction of the FAD cofactor. In our previous studies of the F1395A and F1395S mutants of rat neuronal nitric oxide synthase, we found that the midpoint reduction potential for the oxidised/hydroquinone flavin transition was not substantially perturbed following mutation (E 12 = -227 mV and -237 mV for the F1395A and F1395S enzymes compared with -229 mV for wild-type) (35) . However, the much lower intensity of the semiquinone signal observed in the F1395A and F1395S FAD domains suggests that the potentials for the oxidised/semiquinone (E 1 ) and semiquinone/hydroquinone (E 2 ) couples of the FAD are perturbed, and possibly inverted in their order on the redox scale, compared to the corresponding couples in the wild-type FAD domain. Quantitative EPR studies, however, are required to confirm this suggestion. By contrast, in the isolated FAD domain and reductase enzyme of P450 BM3 there is a major effect on mutating residue W1046. The midpoint potential for the 2-electron reduction of the FAD (E 12 ) is increased by ~100 mV in both mutants, and the semiquinone is by guest on November 19, 2017 http://www.jbc.org/ Downloaded from substantially destabilized with respect to the hydroquinone to such an extent that no optical signal indicative of the semiquinone species is observed during equilibrium redox titrations. The net result is that the potential of the FAD is now much closer to that of the FMN (E 12 = ~-220 mV for W1046A and W1046H FAD domain compared to -203 mV for the FMN in wild-type P450 BM3 reductase) (31) . The elevated flavin reduction potential in the mutant proteins provides a larger driving force for hydride transfer from NAD(P)H (E = -320 mV) to the FAD, but reduces the driving force for inter-flavin electron transfer. Reduction of wild-type FAD domain and reductase enzyme by NADPH to the 2-and 4-electron levels, respectively, is not complete (e.g. 7, 8) owing to the relatively close proximity of the FAD and NADPH potentials. The W1046A and W1046H FAD domains and reductase enzymes, on the other hand, are reduced essentially to the 2-and 4-electron levels by NAD(P)H, since the flavin redox couples are at least ~100 mV more positive than that of NAD(P)H.
Despite the increased potential of the FAD in the W1046H mutant, it is notable that the steady-state rate of cytochrome c reduction with NADPH as reducing coenzyme is essentially identical for both the W1046H and wild-type reductase enzymes (Table 2) . Electron transfer to cytochrome c occurs from the FMN cofactor, and this suggests that the rate of inter-flavin electron transfer is not ratelimiting in W1046H reductase, despite the smaller driving force for this reaction. The distance between these two flavins is a major factor in maintaining rapid rates for electron tunnelling in proteins, and to some extent short tunnelling distances will buffer changes in tunnelling rate attributed to changes in driving force, such that tunnelling per se does not become rate limiting during steady-state turnover. In the crystal structure of CPR, the FAD and FMN cofactors are separated by ~4 Å, but internal electron transfer is relatively slow (35 to 70 s -1 depending on conditions for human CPR [29, 39] ). In CPR, however, the rate of inter-flavin electron transfer is affected by solution viscosity and ligand binding, suggesting that the rate of electron transfer is controlled by an adiabatic process. In such circumstances, the effects of a change in driving force on the tunnelling rate constant would be buffered by the slower adiabatic processes that control the rate of inter-flavin electron transfer.
An important observation is made by comparing the steady-state rates of electron transfer to artificial electron acceptors (ferricyanide and cytochrome c) with those for stopped-flow reduction of the flavin in wild-type and W1046A/H FAD/reductase domains by NAD(P)H. Analyses of flavin reduction rate constants in the W1046A enzymes suggested initially that the observed rate constant might be too slow to support steady-state turnover activity. This anomaly was resolved, however, following comparison of stopped-flow traces for (i) the W1046A enzymes mixed with NAD(P)H and (ii) the W1046A enzymes mixed with buffer. It is clear that a very rapid phase of flavin absorption change is lost in the mixing time of the instrument. This phase accounts for a substantial proportion of the overall flavin absorption change in the W1046A mutants and must occur at >800 s -1 . At present, we cannot rule out that a similar fast phase also occurs with the wild-type and W1046H enzymes, although the amplitude in these enzymes is clearly lower than in W1046A. The mechanistic origin of this fast phase is uncertain, but it is clear that the flavin becomes partially reduced in this kinetic phase. We suggest that electron transfer to ferricyanide can occur following completion of this kinetic phase.
Concluding Remarks. We have generated the W1046A and W1046H mutant FAD and reductase domain proteins of P450 BM3 and demonstrated a substantial switch in coenzyme specificity from NADPH to NADH. Removal of the flavinshielding tryptophan clearly facilitates more effective interactions with the NADH nicotinamide, and highlights the importance of this residue (in addition to the 2' phosphate-binding region) in controlling pyridine nucleotide selectivity in P450 BM3. Potentiometric studies indicate that the FAD in these enzymes no longer stabilizes a neutral, blue semiquinone species and that the midpoint reduction potential for the 2-electron reduction of the flavin (E 12 ) is elevated by ~ 100 mV in comparison with wild-type. Changes in solvent exposure of the flavin isoalloxazine ring system likely contribute significantly to the change in reduction potential. The destabilization of the flavin blue semiquinone species in the mutant proteins likely contributes to the stabilisation of FADH 2 -NAD(P) + charge-transfer species following flavin reduction by coenzyme. The P450 BM3 system has potential applications as a regioand stereo-specific biocatalyst. The ability to substantially switch the coenzyme specificity of P450 BM3 towards that of NADH makes it more attractive as an industrial biocatalyst, and several potential industrial applications for the enzyme have already been reported (e.g. 23, 42, 44, 45) . 
364 ± 25 23 ± 6 6.9 ± 0. Anaerobic spectroelectrochemical titrations were performed as described in the Experimental section. Panel A shows selected spectra from the redox titration of the W1046H FAD domain (ca 60 µM). The inset shows a fit of data at the oxidised flavin maximum (462 nm) to a 2-electron Nernst function (equation 3), producing a midpoint reduction potential for the two electron reduction of the flavin, E 12 = -224 ± 3 mV. Panel B shows a similar data set for the W1046A FAD domain. The inset shows a data plot at 475 nm (at the oxidised flavin maximum for this enzyme), producing a value of E 12 = -220 ± 3 mV. There is no obvious accumulation of semiquinone observed during either redox titration. Arrows indicate direction of absorption change in the reductive direction. 
